HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Communication, education can break taboo of sexual dysfunction in patients with cancer
-
- When loss becomes personal: Reflections on one of our own Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA grants orphan drug designation for APTO-253 for AML
- FDA grants orphan drug designation to AG-120 for AML
- FDA grants orphan drug designation to ImMucin for multiple myeloma
- FDA grants priority review to MM-398 for metastatic pancreatic cancer
- ASCO creates framework to measure value of cancer treatment
- Genomic data may better classify lower-grade glioma than histology
- Intraperitoneal chemotherapy prolongs OS in advanced ovarian cancer
-
- Mohs micrographic surgery may effectively treat rare hidradenocarcinoma
- Pharmacist-managed medication refill clinics ease physician workload
- Promoter mutations redefine molecular subgroups of gliomas
- PTEN, KLLN mutations provide insight into Cowden disease-related endometrial cancer
- Sociodemographic factors affect thyroid cancer survival rates in young adults
- Sunitinib benefits some patients with non-clear cell renal cell carcinoma
- Immunology chairman receives award for cancer research
- ISTH presents Grant Medal to pediatrics professor
-
- Nurse researcher named journal editor
- Society of breast surgeons installs new president
- University selects chair for newly created otolaryngology department
- 30-month complete response serves as PFS surrogate for follicular lymphoma
- Activating KIR genes influence MDS risk, outcome
- Carfilzomib significantly improves PFS in relapsed multiple myeloma
- DCIS survival benefit from surgery varies by nuclear grade
- Early reduction in CTCs leads to survival benefit in prostate cancer
-
- ECX chemotherapy shows some benefit without OS improvement in advanced esophageal cancer
- Investigational compound targets FGFR pathway
- KEYNOTE-001: Findings support pembrolizumab in melanoma
- Lower dose of polatuzumab vedotin safe, effective for follicular lymphoma
- Mismatch repair deficiency predicts response to pembrolizumab in several cancer types
- Mutational profiles of HPV-positive, HPV-negative tumors differ
- Nedaplatin plus docetaxel ‘new standard of treatment’ for advanced squamous lung carcinoma
- Neratinib prolongs invasive DFS in HER-2–positive early-stage breast cancer
-
- Novel recombinant Factor VIII appears safe, effective in severe hemophilia A
- Obinutuzumab, bendamustine significantly extend PFS in relapsed non-Hodgkin's lymphoma
- Pacritinib improves symptom control, reduces spleen volume in patients with myelofibrosis
- Palbociclib plus hormone therapy slows progression of HR-positive breast cancer
- Pediatric soft tissue sarcoma survivors at risk for chronic medical conditions
- Pembrolizumab shows promise for advanced bladder cancer
- POPLAR: Inhibition of the PD-L1/PD-1 pathway may improve survival in NSCLC
- Protocol safely guides perioperative management of dabigatran
-
- Researchers find Inlyta/TACE safe, well-tolerated in Chinese patients with HCC
- Statin, metformin combination reduces prostate cancer mortality, particularly among obese men
- Whole-lung radiation may not be necessary in favorable histology Wilms' tumor responders
- Perspectives from ASCO 2015: A HemOnc Today Special Report